Test Price
2,800 AED✅ Home Collection Available
NCF2 Gene Chronic Granulomatous Disease Type 2 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين NCF2 لمرض الورم الحبيبي المزمن (النوع الثاني) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited sequencing and bioinformatics pipeline.
- Premium Logistics: Hospital‑grade Home Collection (8 AM‑11 PM) with ISO‑certified cold‑chain transport and exclusive VIP Mobile Phlebotomy for children and adults.
- Clinical Guidance: Complimentary telephonic Post‑Test Clinical Guidance by a DHA‑licensed consultant to interpret NCF2 results in your clinical context.
- Insurance: Direct Billing Verification – send your Emirates ID & insurance card via WhatsApp +971 54 548 8731.
Comprehensive Overview of the NCF2 NGS Test
This advanced genetic test employs Next‑Generation Sequencing (NGS) to analyze the entire NCF2 gene, detecting single nucleotide variants, small insertions/deletions, and large copy number changes. It definitively diagnoses autosomal recessive, cytochrome b‑positive chronic granulomatous disease (CGD) type 2, empowering tailored immunology, dermatology, and haematology management.
يُحلل هذا الفحص جين NCF2 بالكامل للكشف عن الطفرات المسببة لمرض الورم الحبيبي المزمن من النوع الثاني (جسدي متنحٍّ، إيجابي السيتوكروم ب)، مما يُمكّن الأطباء من وضع خطة علاجية دقيقة.
| Feature | Our NGS NCF2 Test | Closest Alternative (Panel/Targeted Sanger) |
|---|---|---|
| Analytical Scope | Full gene sequencing + deletion/duplication analysis | Selected exons only; may miss deep intronic or regulatory variants |
| Methodology | NGS (Illumina platform, ISO 15189 validated) | Sanger sequencing – lower throughput |
| Turnaround Time | 3‑4 weeks | 4‑6 weeks or longer for multiple exons |
| Price (AED) | 2800 AED | 2400‑3000 AED (limited coverage) |
Physician Insight & Safety Protocol
“As a clinical pathologist, I want to reassure families that while this test provides a definitive molecular diagnosis, it must always be correlated with neutrophil function assays and clinical phenotype. A positive NCF2 result enables early prophylactic antimicrobials and candidacy for curative stem cell transplantation, but a negative result does not exclude other CGD subtypes. Always consult your doctor before altering any medication.”
— Dr. PRABHAKAR REDDY, DHA License 61713011
⚠ Clinical Notice: Do not discontinue prescribed medication without consulting your treating physician. This genetic test aids diagnosis but does not replace continuous clinical monitoring.
Safety & Exclusion Criteria
- Exclusion criteria for testing: Patients who have received a blood transfusion within the last 4 weeks, or those with active leukocytosis from acute infection, as donor DNA may mask endogenous genotype.
- Children requiring special protection: All minor sample collections comply with UAE Child Data Safeguarding (CDS) Law 2026; a legal guardian must provide informed consent.
- Emergency Red Flags: If the patient develops high fever, rapidly enlarging abscess, severe lymphadenitis, or respiratory distress, proceed to the nearest emergency department immediately—urgent infectious management takes precedence over elective genetic testing.
Frequently Asked Questions – NCF2 Genetic Testing
1. Who should consider this NCF2 gene test?
Individuals with recurrent severe bacterial/fungal infections, a family history of early‑onset granulomatous disease, or unexplained granulomas should consider this targeted genetic analysis. ينبغي للأفراد المصابين بالتهابات بكتيرية/فطرية متكررة، أو وجود تاريخ عائلي لمرض الورم الحبيبي المزمن، أو وجود أورام حبيبية غير مفسَّرة، التفكير في إجراء هذا الفحص الجيني المتخصص.
2. What does a positive NCF2 mutation result mean?
A positive result confirms the diagnosis of autosomal recessive cytochrome b‑positive chronic granulomatous disease type 2, enabling precise prognosis and targeted prophylactic interventions. تؤكد النتيجة الإيجابية تشخيص مرض الورم الحبيبي المزمن المتنحي، إيجابي السيتوكروم ب من النوع الثاني، مما يسمح بوضع خطة وقائية وعلاجية موجَّهة.
3. How is the sample collected and what safety measures protect my child?
Our DHA‑licensed phlebotomists collect a small venous blood sample or a finger‑prick FTA card in your home, strictly adhering to UAE CDS Law 2026 for minors and ISO‑certified cold‑chain transport. يجمع مسعفونا المرخصون من هيئة الصحة بدبي عينة دم وريدي صغيرة أو بطاقة FTA بنظام التنقيط، مع الالتزام الصارم بقانون حماية بيانات الطفل (CDS) لعام 2026 ونظام النقل المبرَّد المعتمد.
DHA/MOHAP Licensed Facility No. 9834453. All tests processed in compliance with Federal Decree‑Law No. 41 of 2024 (Medical Liability), Art. 87, UAE PDPL, and CDS Law 2026.
ISO 9001:2015 Cert: INT/EGQ/2509DA/3139 – assuring quality management across pre‑analytical, analytical, and post‑analytical phases.
For immediate booking or insurance verification, WhatsApp +971 54 548 8731 (same line for telephonic post‑ consultation). Home collection available daily 8 AM – 11 PM. No upfront payment with approved insurance.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians